P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
Main Authors: | M. K. Leabman, G. Hernandez, C. M. Ng, J. Tang, D. Pandya, K. C. Hart, K. Li, P. R. Hinton, J. So, I. Qazi, C. Y. Cheah, W. S. Kim, E. Budde, A. K. Gopal, T. Manley, C. H. Takimoto, A. M. Sinclair, S. F. Carroll, B. A. Keyt, M. F. Kotturi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847968.95263.25 |
Similar Items
-
P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
by: Kevin C. Hart, et al.
Published: (2023-08-01) -
Structure, Function, and Therapeutic Use of IgM Antibodies
by: Bruce A. Keyt, et al.
Published: (2020-10-01) -
Adjunctive IgM-enriched immunoglobulin therapy with a personalised dose based on serum IgM-titres versus standard dose in the treatment of septic shock: a randomised controlled trial (IgM-fat trial)
by: Giacomo Grasselli, et al.
Published: (2021-02-01) -
1078 Agonistic CD40 IgM antibodies enhance immune responses beyond that of IgGs
by: Umesh Muchhal, et al.
Published: (2023-11-01) -
Supernovae and the IGM
by: Binney, J
Published: (2000)